ArticleFrontiers in cardiovascular medicine2025
Serum periostin as a novel biomarker and therapeutic target in coronary heart disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) remains a significant global contributor to morbidity and mortality, necessitating a deeper understanding of its molecular mechanisms. This study aimed to identify and analyze differentially expressed genes associated with CAD, assess their functional enrichment, and construct protein-protein interaction (PPI) networks to elucidate the molecular mechanisms underlying the disease. Methods: Data integration from two Gene Expression Omnibus datasets (GSE66360 and GSE42148) was performed using bioinformatics tools, with batch effects corrected via the R package sva. Differential gene expression analysis was conducted using the limma package in R, enabling identification of genes with statistically significant expression differences between patients with CAD and healthy controls. Results: A total of 704 differentially expressed genes were identified, with 476 upregulated and 228 downregulated genes in CAD samples. Conclusion: This integrated bioinformatics analysis provided valuable insights into the molecular landscape of CAD, highlighting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.